{
  "submission_id": "367789ee-9e5d-4a16-9c27-30d475736dab",
  "compliance_id": "TEST-FINAL-1753816969",
  "ai_content_generated": false,
  "seo_fields_populated": false,
  "seo_data": {},
  "full_submission": {
    "id": "367789ee-9e5d-4a16-9c27-30d475736dab",
    "compliance_id": "TEST-FINAL-1753816969",
    "product_name": "Opdivo Plus",
    "generic_name": "nivolumab-ipilimumab",
    "indication": "Unresectable malignant pleural mesothelioma",
    "therapeutic_area": "Oncology",
    "seo_reviewer_name": "SEO Expert",
    "seo_reviewer_email": "seo@3cubed.com",
    "nct_number": null,
    "sponsor": null,
    "development_stage": null,
    "line_of_therapy": null,
    "patient_population": null,
    "route_of_administration": null,
    "combination_partners": null,
    "primary_endpoints": null,
    "geographic_markets": null,
    "key_biomarkers": null,
    "target_age_groups": null,
    "client_reviewer_name": null,
    "client_reviewer_email": null,
    "mlr_reviewer_name": null,
    "mlr_reviewer_email": null,
    "submitter_email": "final.test@pharma.com",
    "submitter_name": "Dr. Final Test",
    "ai_processing_status": "pending",
    "workflow_stage": "draft",
    "priority_level": "high",
    "created_at": "2025-07-29T19:22:49.494343+00:00",
    "updated_at": "2025-07-29T19:22:49.494497+00:00",
    "ai_generated_content": null,
    "seo_keywords": null,
    "meta_title": null,
    "meta_description": null,
    "last_updated": null,
    "qa_status": null,
    "qa_score": null,
    "qa_feedback": null,
    "error_message": null,
    "mechanism_of_action": null,
    "dosage_form": null,
    "administration_route": null,
    "treatment_setting": null,
    "key_differentiators": null,
    "clinical_benefits": null,
    "client_reviewer": null,
    "geography": null,
    "raw_input_content": "\n    Product: Opdivo Plus (nivolumab + ipilimumab)\n    Indication: First-line treatment of unresectable malignant pleural mesothelioma\n    \n    Key Clinical Data:\n    - CheckMate 743 trial\n    - Overall Survival: 18.1 vs 14.1 months (HR 0.74, p=0.002)\n    - 3-year OS rate: 23% vs 15%\n    - Durable responses observed\n    \n    Target Audience: Oncologists, thoracic surgeons\n    Key Message: First immunotherapy combination approved for mesothelioma\n    "
  }
}